BeiGene | Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma

A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

Beigene Study ID

BGB-3111-306

ClinicalTrials.gov ID

NCT04002297

EudraCT Number

2023-509908-15-00

China Drug Trials ID

CTR20211594

Study Overview

Sex: All

Age: 60 Years / N/A

No Study Documents

Study Overview

Sex: All

Age: 60 Years / N/A

No Study Documents